Thursday, September 08, 2022 9:30:53 AM
Please. There was no original plan to rewrite. RDGL presented an outline of an animal test plan at May 20 meeting. At that meeting FDA requested a detailed animal test plan and what they expected it to contain. RDGL drafted a detailed plan and per June 28 update tweet gave draft to JHU to review. We now know per late August update, JHU has since had to verify they could actually accomplish plan before commenting further. And per that August update it remains uncertain JHU can grow the rabbit tumors to sufficient size.
Per primary literature Kayak cited in prior comments, growing these rabbit tumors to sufficient size is a trivial matter to someone well versed in doing so. So FDA views this as a trivial matter. So when RDGL comes back with detail plan more than three months after FDA request, it sure doesn't look like RDGL is in any hurry.
We now know they delay was because JHU isn't well versed in the rabbit tumor growing art yet. What JHU brings is already certified in IsoPet and they have the veterinary PET scan equipment to verify containment per plan. FDA reviewers won't know background reason for delay until they actual review what RDGL has sent them.
Per primary literature Kayak cited in prior comments, growing these rabbit tumors to sufficient size is a trivial matter to someone well versed in doing so. So FDA views this as a trivial matter. So when RDGL comes back with detail plan more than three months after FDA request, it sure doesn't look like RDGL is in any hurry.
We now know they delay was because JHU isn't well versed in the rabbit tumor growing art yet. What JHU brings is already certified in IsoPet and they have the veterinary PET scan equipment to verify containment per plan. FDA reviewers won't know background reason for delay until they actual review what RDGL has sent them.
Recent RDGL News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:45:22 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/28/2026 08:44:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
